SCHEMBL6097903

SCHEMBL6097903

CCN1C(=O)C(=O)N(c2ccc(Cl)cc2C)C1=S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
MAPT P10636 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 3/20 0.39
GAA P10253 2/20 0.39
PKM P14618 2/20 0.39
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TNFRSF1A P19438 2/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
POLB P06746 2/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
MDM2 Q00987 1/20 0.37
AKR1C3 P42330 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6099362 0.89 MEN1 (0.43) ALDH1A1KDM4ETNFRSF1AMEN1KMT2A
SCHEMBL6096783 0.74 PARK7 (0.46) ALDH1A1MAPTKDM4EMAPK1GAA
SCHEMBL6097864 0.73 MEN1 (0.40) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL8527399 0.73 KMT2A (0.43) ALDH1A1MAPTKDM4EGAATP53
SCHEMBL11608600 0.73 MEN1 (0.50) ALDH1A1MAPTKDM4ETDP1MEN1
SCHEMBL6097897 0.71 NPC1 (0.44) ALDH1A1MAPTKDM4EMAPK1GAA
SCHEMBL10704901 0.70 MGLL (0.55) ALDH1A1MAPTKDM4EMAPK1PKM
SCHEMBL8710977 0.70 KMT2A (0.44) ALDH1A1TP53MEN1KMT2APOLB
SCHEMBL5903417 0.69 ESR1 (0.61) MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL6095067 0.69 MEN1 (0.43) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US claimed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US claimed
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US disclosed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis FFAR4, FFAR1, MSR1 ALDH1A1 896/4885MAPT 4387/4885KDM4E 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.